MACROH2A2

Across TCGA pan-cancer cohorts, MACROH2A2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated MACROH2A2 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher MACROH2A2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated MACROH2A2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LUAD show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where MACROH2A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	II,III,IV	0.416	0.643	.024	6	view →
CCRCC	OS	Quartile	III,IV	0.990	0.580	.018	5	view →
LUAD	OS	Tertile	All	0.838	0.540	.034	3	view →
GBM	OS	Median	All	0.465	0.301	.017	2	view →
HNSC	DFS	Quartile	IV	0.693	0.923	.036	1	view →
LSCC	DFS	Tertile	All	0.406	0.866	.033	1	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

MACROH2A2–PDAC (OS)

Open the PDAC breakdown →